^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    misitatug blivedotin (RC88)

    i
    Other names: RC88, RC88-ADC, RC-88, RC 88
    Associations

    News

    Trials
    Company:
    Rongchang Pharma
    Drug class:
    Microtubule inhibitor, Mesothelin-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    12d
    RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=43, Completed, RemeGen Co., Ltd. | Recruiting --> Completed | N=88 --> 43 | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Platinum resistant
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    12d
    A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=198, Completed, RemeGen Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    28d
    A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=41, Completed, RemeGen Co., Ltd. | Active, not recruiting --> Completed | Phase classification: P1 --> P1/2 | N=81 --> 41 | Trial primary completion date: Jun 2025 --> Nov 2025
    Trial completion • Phase classification • Enrollment change • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    12ms
    A Phase I /IIa Study of RC88-ADC in Subjects with Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, RemeGen Co., Ltd. | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    12ms
    A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=81, Active, not recruiting, RemeGen Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    12ms
    A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=221, Recruiting, RemeGen Co., Ltd. | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    PD-1 (Programmed cell death 1)
    |
    Avastin (bevacizumab) • docetaxel • Aidixi (disitamab vedotin) • misitatug blivedotin (RC88)
    1year
    A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=221, Recruiting, RemeGen Co., Ltd. | Phase classification: P1 --> P1/2 | N=25 --> 221
    Phase classification • Enrollment change
    |
    PD-1 (Programmed cell death 1)
    |
    Avastin (bevacizumab) • docetaxel • Aidixi (disitamab vedotin) • misitatug blivedotin (RC88)
    over1year
    RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=88, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    misitatug blivedotin (RC88)
    almost2years
    A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, RemeGen Co., Ltd. | Trial completion date: May 2024 --> Sep 2025 | Trial primary completion date: Dec 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    2years
    A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, RemeGen Co., Ltd. | N=51 --> 200
    Enrollment change • Metastases
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    2years
    A Study of RC88 Combined With JS001 for Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=82, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jul 2023
    Enrollment open • Trial initiation date
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)
    2years
    A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=81, Recruiting, RemeGen Co., Ltd. | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    misitatug blivedotin (RC88)